Factors associated with remission included older age, HbA1c, weight loss from diagnosis to 2019, previous bariatric surgery
WEDNESDAY, Nov. 3, 2021 (HealthDay News) — About 5 percent of adults aged 30 years and older in Scotland with type 2 diabetes were in remission in 2019, according to a study published online Nov. 2 in PLOS Medicine.
Mireille Captieux, M.B.Ch.B., M.P.H., from the University of Edinburgh in the United Kingdom, and colleagues conducted a cross-sectional study to estimate the prevalence of type 2 diabetes remission in adults in Scotland aged 30 years and older. Remission of type 2 diabetes was defined as all hemoglobin A1c (HbA1c) values <48 mmol/mol in the absence of glucose-lowering therapy for a continuous duration of ≥365 days before the last recorded HbA1c in 2019 and was assessed between Jan. 1 and Dec. 31, 2019. Data were included for 162,316 individuals, all of whom had at least one HbA1c value of ≥48 mmol/mol at or after type 2 diabetes diagnosis.
The researchers found that 7,710 people (4.8 percent) were in remission of type 2 diabetes. Factors associated with remission included age (odds ratio, 1.48 for ≥75 versus 45 to 54 years), HbA1c (odds ratio, 1.31 for <48 versus 48 to 52 mmol/mol at diagnosis), no previous history of glucose-lowering therapy (odds ratio, 14.6), weight loss from diagnosis to 2019 (odds ratio, 4.45 for ≥15 kg versus 0 to 4.9 kg weight gain), and previous bariatric surgery (odds ratio, 11.9).
“We have been able to show, for the first time, that one in 20 people in Scotland with type 2 diabetes achieve remission,” Captieux said in a statement. “This is higher than expected and indicates a need for updated guidelines to support clinicians in recognizing and supporting these individuals.”
Two authors disclosed financial ties to the pharmaceutical industry.
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Report Highlights Substance Use in Young Adults in U.S. in 2025
Considerable Gaps Identified in LDL Cholesterol Control
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk